- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05725590
A Multicenter Randomized Controlled Study of External Pancreatic Duct Stents in Pancreaticoduodenectomy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pancreatic cancer, with its associated poor prognosis, is one of the most insidious and lethal cancers globally. Indeed, pancreatic cancer has been listed as the fourth leading cause of cancer-related deaths in developed countries, and it may replace colorectal cancer as the second-leading cause of cancer-related deaths by 2030. Pancreaticoduodenectomy is the standard treatment for periampullary carcinoma, especially pancreatic head tumors. However, the incidence of postoperative complications, especially postoperative pancreatic fistula, remains as high as 25%-50%, which limits the dissemination of pancreaticoduodenectomy.
An external pancreatic duct stent is one of the methods used to prevent pancreatic fistula. A large number of studies, including prospective randomized trials as well as meta-analyses, have shown that external pancreatic duct stents significantly decrease the rate of pancreatic fistula and shorten the length of hospital stay. Paradoxically, several studies have shown that external pancreatic duct stents have no effect and may even increase the incidence of postoperative pancreatic fistula. In a meta-analysis, Dong et al. observed that the use of an external pancreatic duct stent was associated with a significantly lower incidence of pancreatic fistula in patients at high risk for pancreatic fistula compared with an internal stent, but there was no definitive conclusion because of the low quality of the evidence.
In 2019, Mungroop et al. proposed the Updated Alternative Fistula Risk Score (ua-FRS) according to the International Study Group of Pancreatic Surgery (ISGPS), which quantitatively validated the risk of pancreatic fistula and assessed the benefits of pancreatic duct stents in patients at different levels of risk. Moreover, ISGPS redefined the classification criteria for pancreatic fistula (Grade A) as a biochemical leak, which had no significant clinical impact on the clinical prognosis. In addition, the position statement by ISGPS indicated that, due to the lack of high-quality evidence, the pancreatic duct stent was not routinely recommended during pancreaticoenteric anastomosis, but external stenting can be considered in high-risk glands. Therefore, it is necessary to systematically re-investigate the safety and effectiveness of external pancreatic duct stents for the prevention and treatment of clinically relevant postoperative pancreatic fistula (CR-POPF) in both high-risk and low-risk patients. This retrospective study was conducted to evaluate the differences between external and internal pancreatic stents using the ua-FRS scoring system, based on the hypothesis that the use of an external stent in high-risk patients could decrease the rates of CR-POPF compared with an internal stent after pancreaticoduodenectomy.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sheng Yan, Doctor
- Phone Number: 13957161680
- Email: shengyan@zju.edu.cn
Study Contact Backup
- Name: Guogang Li, Doctor
- Phone Number: 13819198620
- Email: liguogangnag@163.com
Study Locations
-
-
-
Hangzhou, China
- Recruiting
- 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
-
Contact:
- Yuancong Jiang, Doctor
- Phone Number: 18868107327
- Email: jiangyuancong@zju.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Pancreatoduodenectomy with pancreaticojejunal mucosa anastomosis was performed;
The patient has no combined organic diseases in the heart, lungs, or kidneys;
- No history of chemotherapy, radiotherapy, upper abdominal surgery, or combined with other tumors; ④ The risk score of the pancreatic fistula of the patient according to the definition of the updated Alternative Fistula Risk Score (ua-FRS). Patients with a ua-FRS score higher than 5% were included in this study.
Exclusion Criteria:
Previous history of other tumors or upper abdominal surgery; ② Multiple lesions and distant metastasis;
- Patients with organic diseases of important organs such as the heart, lung, and kidney, who cannot tolerate surgery, or patients who are more than 75 years old or less than 18 years old; ④ Other measures were performed to prevent pancreatic fistula, such as fibrin glue sealing, which may affect the accuracy of this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: external pancreatic duct stent
|
All pancreaticoduodenectomies were performed by the same surgical team at our pancreatic center throughout the study period.
According to the preoperative laboratory results, medical imaging data, and intraoperative conditions, the laparoscopic or open pancreaticoduodenectomy, or pylorus-preserving pancreaticoduodenectomy was performed at the discretion of the individual surgeon.
The child's technique was implemented to achieve digestive tract reconstruction, and all patients underwent a duct-to-mucosa pancreaticojejunostomy.
The external pancreatic duct stent left the other end exteriorized through the proximal jejunum via a small enterotomy that was fixed in the abdominal wall.
|
EXPERIMENTAL: internal pancreatic duct stent
|
All pancreaticoduodenectomies were performed by the same surgical team at our pancreatic center throughout the study period.
According to the preoperative laboratory results, medical imaging data, and intraoperative conditions, the laparoscopic or open pancreaticoduodenectomy, or pylorus-preserving pancreaticoduodenectomy was performed at the discretion of the individual surgeon.
The child's technique was implemented to achieve digestive tract reconstruction, and all patients underwent a duct-to-mucosa pancreaticojejunostomy.
The internal pancreatic duct stent, a silicone catheter with multiple side pores, was inserted into the main pancreatic duct and the other end was placed in the jejunum cavity.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidence of CR-POPF
Time Frame: 1 month after the surgery completion
|
The primary endpoint of this retrospective study was the incidence of CR-POPF, which was graded according to the definition set forth by ISGPS in 2016.
|
1 month after the surgery completion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidence of other complications
Time Frame: 1 month after the surgery completion
|
The secondary endpoints of this retrospective study included the incidence of delayed gastric emptying (DGE), postoperative pancreatic hemorrhage (PPH), bile leakage, infection and mortality, which were graded according to the Clavien-Dindo Classification.
|
1 month after the surgery completion
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Sheng Yan, Doctor, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
- Principal Investigator: Yuancong Jiang, Doctor, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-0976
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Fistula
-
Rigshospitalet, DenmarkRecruitingFistula PancreaticDenmark
-
Peking Union Medical College HospitalRecruiting
-
Changzhou Second People's Hospital affiliated with...RecruitingPostoperative Pancreatic FistulaChina
-
Junjie XiongRecruitingPancreaticoduodenectomy | Postoperative Pancreatic FistulaChina
-
Instituto de Investigación Sanitaria AragónCompletedPancreas Disease | Fistula PancreaticSpain
-
Mansoura UniversityCompletedPancreatic Fistula After PancreaticoduodenectomyEgypt
-
Casa di Cura Dott. PederzoliFondazione Banca dei Tessuti di Treviso onlusCompletedPost Operative Pancreatic Fistula | Pancreatic Resection | Biological DressingItaly
-
Institute of Liver and Biliary Sciences, IndiaRecruitingPost Operative Pancreatic FistulaIndia
-
Karolinska University HospitalUniversity Hospital, Linkoeping; Lund University Hospital; Sahlgren´s University... and other collaboratorsUnknownPost Operative Pancreatic FistulaSweden
-
Technische Universität DresdenGerman Cancer Research Center; KKS DresdenNot yet recruitingPeriampullary Cancer | Postoperative Pancreatic FistulaGermany
Clinical Trials on External pancreatic duct stent
-
AdventHealthCompletedWalled Off Necrosis | Necrotizing PancreatitisUnited States
-
Instituto Ecuatoriano de Enfermedades DigestivasActive, not recruitingBiliary Tract DiseasesEcuador
-
Karolinska University HospitalUniversity Hospital, Linkoeping; Lund University Hospital; Sahlgren´s University... and other collaboratorsUnknownHealing Time of Post Operative Pancreatic FistulasSweden
-
Washington University School of MedicineNorthwestern University; University of OklahomaCompletedEndoscopic Retrograde Cholangiopancreatography (ERCP) | Bile Duct CannulationUnited States
-
Johns Hopkins UniversityWithdrawnPancreatic CancerUnited States
-
University Hospital, AngersCompleted
-
Shanghai Zhongshan HospitalRenJi Hospital; First Affiliated Hospital Xi'an Jiaotong University; The Affiliated... and other collaboratorsNot yet recruiting
-
Technical University of MunichKU Leuven; Northern State University, Russia; Latvijas Universitates MedicinasCompletedPost-ERCP Acute PancreatitisBelgium, Germany, Latvia, Russian Federation
-
University Hospital, ToulouseCompleted
-
Changhai HospitalEnrolling by invitationChronic PancreatitisChina